Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

Health Policy

Volumn 94, Issue 3, 2010, Pages 221-229

  Wettermark, Björn ^a   Godman, Brian ^a,b,c   Neovius, Martin ^a   Hedberg, Niklas ^d   Mellgren, Tor Olov ^c   Kahan, Thomas ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d Dental and Pharmaceutical Benefits Agency   (Sweden)

^e DANDERYD HOSPITAL   (Sweden)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Guidelines; Hypertension; Prescribing; Reimbursement

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; CILAZAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPROSARTAN; FELODIPINE PLUS METOPROLOL; FOSINOPRIL; IRBESARTAN; LABETALOL; LERCANIDIPINE; LOSARTAN; METHYLDOPA; METOPROLOL; PINDOLOL; PROPRANOLOL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CAPITAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH ECONOMICS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PHARMACEUTICAL CARE; PRESCRIPTION; PUBLIC HEALTH SERVICE; REIMBURSEMENT; SWEDEN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; HYPERTENSION; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH, REIMBURSEMENT; PREGNANCY; SWEDEN;

EID: 77149139476     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2009.09.014     Document Type: Article

References (33)

1. Kaplan W., Laing R. Priority medicines for Europe and the World Project. A public health approach to innovation 2004, WHO, Geneva.
2. Cutler J.A., Sorlie P.D., Wolz M., Thom T., Fields L.E., Roccella E.J. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008, 52:818-827.
3. Wolf-Maier K., Cooper R.S., Banegas J.R., Giampaoli S., Hense H.W., Joffres M., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. Journal of the American Medical Association 2003, 289:2363-2369.
4. Staessen J.A., Li Y., Thijs L., Wang J.G. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertension Research 2005, 28:385-407.
5. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
6. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2007, 28:1462-1536.
7. Swedish Council on Technology Assessment in Health Care (SBU). Moderately Elevated Blood Pressure. SBU report 170. Stockholm; 2004.
8. Walley T., Duggan A.K., Haycox A.R., Niziol C.J. Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. Journal of the Royal Society of Medicine 2003, 96:525-531.
9. Jackevicius C.A., Tu K., Filate W.A., Brien S.E., Tu J.V. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Canadian Journal of Cardiology 2003, 19:1359-1366. Canadian Cardiovascular Outcomes Research Team.
10. Greving J.P., Denig P., van der Veen W.J., Beltman F.W., Sturkenboom M.C., de Zeeuw D., et al. Does comorbidity explain trends in prescribing of newer antihypertensive agents?. Journal of Hypertension 2004, 22:2209-2215.
11. Frisk P., Mellgren T.-O., Hedberg N., Berlin A., Granath F., Wettermark B. Utilization of angiotensin receptor blockers in Sweden-combining survey and register data to study adherence to prescribing guidelines. European Journal of Clinical Pharmacology 2008, 64:1223-1229.
12. Matchar D.B., McCrory D.C., Orlando L.A., Patel M.R., Patel U.D., Patwardhan M.B., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Annals of Internal Medicine 2008, 148:16-29.
13. Anon. Working guidelines for pharmaceutical reimbursement review. Reference 1023/2003. Solna: dental and pharmaceutical benefits agency; 2008 [online]. Available from: [accessed April 17, 2009]. http://www.tlv.se/Upload/Genomgangen/guidelines-pharmaceutical-reimbursement.pdf.
14. Moïse P, Docteur E. OECD Health Working Papers No. 28. Pharmaceutical pricing and reimbursement in Sweden; July 26, 2007. DELSA/HEA/WD/HWP(2007)5.
15. Wettermark B., Godman B., Andersson K., Gustafsson L.L., Haycox A., Bertele V. Recent national and regional drug reforms in Sweden-implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008, 26:537-550.
16. Godman B., Wettermark B., Hoffmann M., Andersson K., Haycox A., Gustafsson L.L. Swedish experience in ambulatory care with multifaceted national and regional drug reforms and initiatives: global relevance. Expert Review of Pharmacoeconomics and Outcomes Research 2009, 9:65-83.
17. Cohen J., Stolk E., Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007, 25:727-734.
18. Hedberg N, Jacob J. A review of medicines for lowering blood pressure-a summary. Solna: Dental and Pharmaceutical Benefits Agency; 2008 [online]. Available from: [accessed April 17, 2009]. http://www.tlv.se/Upload/Genomgangen/review-blood-pressure.pdf.
19. Wettermark B., Jacobsson B., Godman B., Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking-an overview of current approaches and their consequences. Applied Health Policy and Health Economy 2009, 7:1-11.
20. Wettermark B., Hammar N., MichaelFored C., Leimanis A., Otterblad Olausson P., Bergman U., et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology Drug Safety 2007, 16:726-735.
21. World Health Organization (WHO) Guidelines for ATC classification and DDD assignment 2008, WHO Collaborating Center for Drug Statistics Methodology, Oslo. http://www.whocc.no/.
22. Hallas J., Støvring H. Templates for analysis of individual-level prescription data. Basic Clinical Pharmacology and Toxicology 2006, 98:260-265.
23. Glenngård A.H., Hjalte F., Svensson M., Anell A., Bankauskaite V. Health systems in transition 2005, WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies, Sweden, Copenhagen.
24. Anell A. Swedish healthcare under pressure. Health Economics 2005, 14:S237-S254.
25. Fischer M.A., Choudhry N.K., Winkelmayer W.C. Impact of medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing?. Health Affairs (Millwood) 2007, 26:800-807.
26. Godman B., Haycox A., Schwabe U., Joppi R., Garattini S. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008, 26:91-98.
27. Aaserud M., Dahlgren A.T., Kosters J.P., Oxman A.D., Ramsay C., Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Systematic Reviews 2006, 2:CD005979.
28. Grimshaw J., Campbell M., Eccles M., Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Family Practice 2000, 17:S11-S18.
29. Soumerai S.B., Ross-Degnan D., Fortess E.E., Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Quarterly 1993, 71:217-252.
30. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal 2008, 29:2388-2442. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology.
31. Cramer J.A., Benedict A., Muszbek N., Keskinaslan A., Khan Z.M. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. International Journal of Clinical Practice 2008, 62:76-87.
32. Kanavos P., Ross-Degnan D., Fortress E., Abelson J., Soumerai S. Measuring, monitoring and evaluating policy outcomes in the pharmaceutical sector. Regulating pharmaceuticals in Europe: striving for efficiency equity and quality 2004, Open University Press, Berkshire, UK. E. Mossialos, M. Mrazek, T. Walley (Eds.).
33. Fahey T., Schroeder K., Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. British Journal of General Practice 2005, 55:875-882.